URGN
UroGen Pharma Ltd.
NASDAQ · USHealthcareBiotechnology
$41.12+2.21%
Price as of Jul 20, 2026
URGN capital
UroGen Pharma Ltd. capital & dividend
Leverage, liquidity, debt coverage and shareholder-distribution metrics.
Leverage
- Debt / equity
- -1.59x
- Net debt / equity
- -0.69x
- Debt / assets
- 0.78x
- Debt / EBITDA
- -1.70x
- Net debt / EBITDA
- -0.74x
Liquidity & coverage
- Current ratio
- 4.69x
- Quick ratio
- 4.28x
- Cash ratio
- 2.80x
- Interest coverage
- -2.81x
- EBITDA / interest
- -3.01x
- Working capital
- $186.8M
Cash & dividend
- FCF / debt
- -0.84x
- Cash flow / debt
- -0.84x
- Dividend per share
- —
- Dividend yield
- —
- Dividend growth 1y
- —
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.